CClinicalTrials.gg
Sign In
CompletedNCT00426998Updated Jan 26, 2007

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

A Phase 2 interventional study of Verteporfin and Bevacizumab in Choroidal Neovascularization and Macular Degeneration, sponsored by Retinal Consultants Medical Group. Completed at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2007-01-26.

Sponsored by Retinal Consultants Medical Group · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).

02

Conditions studied

  • Choroidal Neovascularization
  • Macular Degeneration

Keywords

  • Choroidal neovascularization due to age-related macular degeneration
03

In context

Macular Degeneration

1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.

This study's enrollment of 30 is below the median of 51 across 985 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

This is the only study on the registry with Retinal Consultants Medical Group as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients are men or women of age 55 or older
  2. Patients have subfoveal CNV due to AMD with lesion size less than or equal to 9 MPS DA
  3. patients have not received previous treatment for subfoveal CNV due to AMD.
  4. Patients have a visual acuity between 20/40 and 20/320-

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received previous treatment for subfoveal CNV, in their study eye including prior PDT, transpupillary thermotherapy (TTT), submacular surgery, drug therapies such as Macugen or other anti-angiogenic compounds, or other local treatment. Previous laser photocoagulation therapy is acceptable, provided it was not subfoveal.
  2. Patients with a known hypersensitivity/allergy to verteporfin, porfimer sodium, or other porphyrins, porphyria or other porphyrin sensitivity, or hypersensitivity to sunlight or bright artificial light.
  3. Patients who use medications that may induce photosensitivity.
  4. Patients who have undergone YAG capsulotomy within the last month.
  5. Subjects currently involved in any experimental procedure within the last 12 weeks.

  6. Female patients who are pregnant, fecund or breast-feeding.

    -

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
30 participants

Interventions

  • DrugVerteporfin
  • DrugBevacizumab
06

What researchers measure

Primary outcomes

  1. percentage of patients losing 3 or more lines of visual acuity

  2. percentage of patients gaining 3 or more lines of visual acuity

  3. mean change from baseline in visual acuity

  4. OCT evidence of active CNV leakage

  5. fluorescein angiographic evidence of active CNV leakage

  6. number of retreatments

07

Study locations

1 site
  • Retinal Consultants Medical Group, Inc.
    Sacramento, California 95819, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00426998
Lead sponsor
Retinal Consultants Medical Group
First posted
Jan 26, 2007
Start date
Apr 2006
Last update
Jan 26, 2007

Study contacts

Joel A Pearlman, M.D., Ph. D.
principal investigator · Retinal Consultants Medical Group, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration→

Start the discussion